Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to -$1.2 million.

  • Contineum Therapeutics' Change in Account Payables fell 28416.29% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$653000.0, marking a year-over-year decrease of 57318.84%. This contributed to the annual value of $1.1 million for FY2024, which is N/A changed from last year.
  • Contineum Therapeutics' Change in Account Payables amounted to -$1.2 million in Q3 2025, which was down 28416.29% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Change in Account Payables ranged from a high of $1.8 million in Q1 2025 and a low of -$1.6 million during Q2 2025
  • Over the past 3 years, Contineum Therapeutics' median Change in Account Payables value was $170000.0 (recorded in 2024), while the average stood at $10000.0.
  • The largest annual percentage gain for Contineum Therapeutics' Change in Account Payables in the last 5 years was 272000.0% (2025), contrasted with its biggest fall of 106705.88% (2025).
  • Quarter analysis of 3 years shows Contineum Therapeutics' Change in Account Payables stood at -$625000.0 in 2023, then soared by 160.48% to $378000.0 in 2024, then plummeted by 423.02% to -$1.2 million in 2025.
  • Its Change in Account Payables stands at -$1.2 million for Q3 2025, versus -$1.6 million for Q2 2025 and $1.8 million for Q1 2025.